Business

Virpax Pharmaceuticals announced that it has acquired exclusive global rights from Nanomerics Ltd. for the use of molecular envelope technology (MET) for delivery of an intranasal formulation of enkephalin for the treatment of PTSD. The company says that PES200 will be delivered via a cartridge-based, pressurized nasal delivery device, presumably the Naltos dry … [Read more...] about Virpax to develop intranasal enkephalin formulation for the treatment of PTSD

Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101 for the treatment of bronchiolitis obliterans syndrome (BOS). According to Altavant, the deal included an upfront … [Read more...] about Altavant Sciences acquires Onspira Therapeutics

Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix's iSPERSE particle engineering technology for development of inhaled formulations of Nocion drugs.  According to the Nocion web site, the company's lead candidate targets refractory chronic cough. … [Read more...] about Pulmatrix announces collaboration with Nocion Therapeutics

ATAI Life Sciences has announced a deal with US-based Neuronasal Inc. for development of intranasal N-acetylcysteine (NAC) for the treatment of mild traumatic brain injury (mTBI, or concussion). ATAI said that it expects initiation of a pilot study in healthy volunteers in February 2020. According to a Neuronasal presentation, the drug would be delivered via the … [Read more...] about ATAI Life Sciences partners with Neuronasal on intranasal N-acetylcysteine for concussion

According to Pulmatrix, the Lung Cancer Initiative at Johnson & Johnson will pay $7.2 million up front plus a $2 million milestone payment for an option "to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception." The $2 million milestone payment will be due on completion of a Phase 1b study of RV1162/PUR1800 … [Read more...] about Pulmatrix announces license agreement with J&J’s Lung Cancer Initiative

CF PharmTech, which says it is developing a variety of OINDPs, announced that it has closed a Series E financing round  that will be used to support development of its pipeline products. The $90 million round was led by Shanghai-based New Alliance Capital. In August 2017, the company said that it had raised $65 million in a Series D round to support development … [Read more...] about CF PharmTech gets $90 million in latest financing round for inhaled drug development

Inhaled drug developer Savara announced that it has entered into a definitive agreement for a private placement of common stock, pre-funded warrants, and milestone warrants with an expected $26.8 million in gross proceeds from sales of the common stock and pre-funded warrants and a potential of up to $75 million if all milestone warrants are exercised. The private … [Read more...] about Savara announces $26.8 million private placement